Navigation Links
Chemo drugs cause cognitive decline in breast cancer patients

Chemobrain is a condition of cognitive decline experienced by several cancer patients receiving chemotherapy. This was confirmed by a recent study conducted on the // effect of chemotherapy on cognitive functions in mice.

Dr. Gordon Winocur of the Baycrest Research Centre for Aging and the Brain carried out the analysis at Trent University in association with Drs. Ian Tannock and Janette Vardy of Princess Margaret Hospital.

The study was published in the September 2006 issue of Pharmacology, Biochemistry and Behavior (Vol. 85, Issue 1) and will be available online next week. The findings were presented at a workshop held in combination with the 8th World Congress of Psycho-Oncology in Venice last week.

"In our study, we identified learning and memory deficits in the mild to moderate range in the drug-treated mice compared to the controls," says Dr. Winocur. "That the deficits were relatively small is encouraging. It's important that cancer patients continue with these drugs and know that if they experience mild to moderate impairments in their cognitive functions, this level of change is potentially manageable."

While there is growing evidence from studies of cancer patients on chemotherapy that the chemobrain effect does exist, many of the studies have suffered from methodological limitations. These include small samples, less than adequate controls and failure to account for other factors, including disease-related complications and stress, which could affect performance.

This latest study, using an animal model, afforded researchers the opportunity to look at the direct effects of chemotherapy drugs on cognitive performance without interference from potentially confounding variables.

In the study, 25 healthy female mice were split into two groups: the drug treatment group received standard doses of methotrexate and 5-fluorouracil (5FU), two drugs widely used in women to prevent recurrence of breast ca ncer; and the control group received a saline solution. Both groups were given their treatments over three weeks.

One week after the final injection they were put through a series of spatial/non-spatial memory tests and conditional rule learning tests in a water maze. The behavioral tasks enabled investigators to assess various aspects of learning and memory associated with different brain regions. The drug treatment group scored lower on the spatial memory task (hippocampus) and the task requiring strategic and working memory components (frontal lobes), especially when there were long delay intervals, compared to the control group. The drug group was not impaired on a cued memory test or in discrimination learning, tasks that are not affected by selective damage to the frontal lobes or hippocampus.

"This indicates that the adverse effects of this treatment regimen of methotrexate and 5FU probably do not extend to all regions of the brain. It appears that the hippocampus and frontal lobes are primarily affected," says Dr. Winocur.

Because the behavioral testing was initiated two weeks after the last treatment and completed within four to five weeks, the study assessed only the short-term effects of the drugs. This is important because it raises the possibility that at longer treatment intervals there might have been some recovery of cognitive function, notes Dr. Winocur.


Related medicine news :

1. Acupuncture May Help Chemotherapy Side Effects
2. Chemotherapy Pill Has Fewer Side Effects Than IV
3. Survival rates in breast cancer patients improved with "Dose Dense Chemotherapy"
4. Therapy Boosts Chemotherapy Effects
5. Chemotherapy Effective for Bladder Cancer
6. Hope for Chemo-Resistant Leukemia Patients
7. New Method Of Delivering Chemotherapy
8. Drug That Is Found To Reduce Heart Damage from Chemo
9. The Benefits Of Chemotherapy For Women With Ovarian Cancer
10. New Compound Could Strengthen The Effect Of Chemotherapy
11. Older Breast Cancer Patients Can Be Effectively Treated With Chemotherapy
Post Your Comments:

(Date:10/13/2017)... ... October 13, 2017 , ... The ... to promote standards of excellence for the field of eating disorders, announces the ... – 25, 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... ... , ... Talented host, actor Rob Lowe, is introducing a ... episode of "Success Files," which is an award-winning educational program broadcasted on PBS ... in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve in ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... -- AllianceRx Walgreens Prime, the combined central specialty pharmacy and ... manager Prime Therapeutics LLC (Prime), today officially began the ... of new signage at its headquarters in ... few other company-owned facilities across the country. This also ... whom will begin to see the AllianceRx Walgreens Prime ...
(Date:9/27/2017)... 27, 2017  Commended for their devotion to personalized service, ... as number one in the South Florida Business Journal,s 50 ... 5000 yearly list, the national specialty pharmacy has found its ... will soon be honored by SFBJ as the 2017 ... Set to receive his award in October, Bardisa said ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest Obamacare ... Bill Cassidy (R-LA) and Lindsey Graham ... that the medical device industry is in an odd ... tax, the 2.3% excise tax on medical device sales ... also want covered patients, increased visits and hospital customers ...
Breaking Medicine Technology: